Clinical Evaluation of a Point of Care (POC) Assay to Identify Phenotypes in the Acute Respiratory Distress Syndrome
NCT ID: NCT04009330
Last Updated: 2025-07-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
480 participants
OBSERVATIONAL
2019-11-22
2026-02-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Study Aim
The purpose of this project is to prospectively identify hyper- and hypo-inflammatory phenotypes in patients with ARDS and determine clinical outcomes associated with each phenotype.
The primary objective of this study is to assess the clinical outcomes in patients with ARDS according to their prospectively defined inflammatory phenotype determined using a POC assay.
Results of group allocation will be blinded to clinical and research staff until database lock.
Secondary Objectives
The secondary objectives of this study are to:
(i) Assess the agreement of the phenotype allocation using the POC assay and the clinical study dataset.
(ii) Assess the stability of phenotype allocation over time
(iii) To test feasibility of delivering a POC assay in the NHS intensive care setting.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ALI/ARDS Clinical Sub-phenotyping Study
NCT06123962
Epidemiological Characteristics and Prediction System of Acute Respiratory Distress Syndrome
NCT06069466
Biomarkers in Exhaled Breath Condensates in Acute Lung Injury: Early Detection and Outcome Predictors
NCT01503723
Stratification of the Acute Respiratory Distress Syndrome - A Second Phase Study
NCT02836444
Arterial pH Selectively Predicts Intensive Care Unit Transfer From the Emergency Department in Obese Patients With Acute Dyspnea
NCT03239730
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Despite decades of research, mortality due to ARDS remains high at 35-46%, with increasing mortality in patients with more severe lung injury. ARDS survivors have significant long term comorbidity with reduced quality of life even 5 years after disease resolution. Various pharmacological agents such as β2 agonists, statins, keratinocyte growth factor and aspirin have been investigated as potential therapies to prevent or treat ARDS, however to date there is no effective pharmacological therapy for ARDS and current treatment strategy is largely supportive.
One reason for the lack of specific pharmacological therapy is likely due to the clinical and biological heterogeneity. It is essential to rapidly identify patients with specific therapy responsive traits to improve our chance of identifying a specific therapy.
Rationale for the Study
ARDS phenotypes have different outcomes and response to therapy.
The clinical and biological heterogeneity in ARDS makes it essential to identify homogenous phenotypes when investigating potential therapies.
A retrospective analysis of the clinical and biological data-set collected as part of two large multicentre studies (ARMA and ALVEOLI) using latent class analysis has identified at least two ARDS phenotypes. Furthermore these two phenotypes could be differentiated using a parsimonious data-set including the presence of shock, metabolic acidosis and a higher inflammatory status (IL-6 and sTNFr1). The hyper-inflammatory phenotype demonstrated significantly worse outcomes when compared to the hypo-inflammatory phenotype with higher mortality and less ventilator free and organ failure free days. In the ALVEOLI study, where low PEEP was compared to high PEEP strategy, the two phenotypes demonstrated a differential response to PEEP suggesting the potential for using this phenotypic classification in identifying a therapy responsive trait.
In addition, in a secondary analysis of the HARP-2 study, a multicentre study investigating the potential of simvastatin as an anti-inflammatory therapy for ARDS, the presence of a hyper- and hypo-inflammatory phenotype was confirmed. The hyper-inflammatory phenotype had a higher 28 day mortality, fewer ventilator free days and organ failure free days. Survival of patients classified as hyper-inflammatory and randomised to simvastatin was improved.
Implementation of a precision medicine approach to identify patients with a therapy response trait is crucial to identify specific therapies to prevent or treat ARDS. Development of a Point of Care (POC) assay for IL-6 and sTNFr1 for prospective confirmation of the inflammatory phenotypes using the parsimonious data-set in patients with ARDS will support a precision medicine approach for this condition.
A POC assay will support precision medicine for ARDS
Studies that show no benefit from an intervention could occur as a result of a variety of reasons including a) the intervention was ineffective, b) the study design was poor or c) patient heterogeneity. Reduction of patient heterogeneity to identify patients with common biological processes will enable the selection of patients with a higher likelihood of therapy response in clinical studies. The identification and institution of therapy for critically ill patients with ARDS needs to occur rapidly in view of the nature of the disease and development of an accurate POC assay is likely to be an essential component in the discovery of effective therapies.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Adults in the Intensive Care Setting
Adults in the Intensive Care Setting
POC Assay
Interventions:
Blood Baseline - up to 40ml Day 3 - up to 40ml
Urine Baseline - 10ml Day 3 - 10ml
Study population:
Adults (18 plus) in ICU units diagnosed with ARDS.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
POC Assay
Interventions:
Blood Baseline - up to 40ml Day 3 - up to 40ml
Urine Baseline - 10ml Day 3 - 10ml
Study population:
Adults (18 plus) in ICU units diagnosed with ARDS.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. ARDS as defined by the Berlin definition (Ranieri et al.) a) Onset within 1 week of identified insult b) Within the same 24-hour time period: i. Hypoxic respiratory failure (PaO2/ FiO2 ratio ≤ 40kPa on PEEP ≥ 5 cmH20\*) ii. Bilateral infiltrates consistent with pulmonary oedema not explained by another pulmonary pathology iii. Respiratory failure not fully explained by cardiac failure or fluid overload
The time of onset of ARDS is when the last ARDS criterion is met.
\*PEEP assumed ≥ 5 cmH20 if on HFNO.
Exclusion Criteria
2. More than 48 hrs after onset of ARDS
3. Receiving ECMO at the time of recruitment
4. Treatment withdrawal imminent within 24 hours
5. DNAR (Do Not Attempt Resuscitation) order (excluding advance directives) in place
6. Declined consent
7. Prisoners
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Northern Ireland Clinical Trials Unit
OTHER
Innovate UK
OTHER_GOV
Queen's University, Belfast
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
DannyMcAuley
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Professor D McAuley
Role: PRINCIPAL_INVESTIGATOR
Queens University Belfast
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St Vincents Hospital
Dublin, Ireland, Ireland
University Hospital Birmingham
Birmingham, England, United Kingdom
Royal Blackburn Hospital
Blackburn, England, United Kingdom
Royal Liverpool University Hospital
Liverpool, England, United Kingdom
University College London
London, England, United Kingdom
Guys and St Thomas Hospital
London, England, United Kingdom
Kings College Hospital
London, England, United Kingdom
Wythenshawe Hospital
Manchester, England, United Kingdom
Manchester Royal Infirmary
Manchester, England, United Kingdom
Freemans Hospital
Newcastle upon Tyne, England, United Kingdom
Nottingham University Hospital
Nottingham, England, United Kingdom
Royal Berkshire Hospital
Reading, England, United Kingdom
Sunderland Royal
Sunderland, England, United Kingdom
Royal Cornwall Hospital
Truro, England, United Kingdom
Edinburgh Royal Infirmary
Edinburgh, Scotland, United Kingdom
Glasgow Royal Infirmary
Glasgow, Scotland, United Kingdom
University Hospital of Wales
Cardiff, Wales, United Kingdom
Royal Gwent Hospital
Newport, Wales, United Kingdom
Royal Victoria Hospital
Belfast, , United Kingdom
Birmingham Heartlands Hospital
Birmingham, , United Kingdom
Imperial College London
London, , United Kingdom
Oxford University Hospitals
Oxford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
ARDS Definition Task Force; Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012 Jun 20;307(23):2526-33. doi: 10.1001/jama.2012.5669.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B19/06
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.